CymaBay Therapeutics, Inc. 4

Accession 0001179110-13-018558

CIK 0001042074operating

View on SEC.gov Company Profile

Filed

Dec 26, 7:00 PM ET

Accepted

Dec 27, 6:43 PM ET

Size

37.8 KB

Accession

0001179110-13-018558

Insider Transaction Report

Form 4

Period: 2013-12-23

CymaBay Therapeutics, Inc.NONE

Van Wart Harold

DirectorPresident and CEO

Transactions

Disposition to Issuer
Stock Option (right to buy)
2013-12-23−9,745→ 0 total
Exercise: $30.21Exp: 2014-01-12→ Common Stock (9,745 underlying)
Award
Stock Option (right to buy)
2013-12-23+6,212→ 6,212 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (6,212 underlying)
Award
Stock Option (right to buy)
2013-12-23+1,257→ 1,257 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (1,257 underlying)
Award
Stock Option (right to buy)
2013-12-23+9,745→ 9,745 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (9,745 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−5,535→ 0 total
Exercise: $39.75Exp: 2018-06-05→ Common Stock (5,535 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−1,493→ 0 total
Exercise: $39.75From: 2008-06-05Exp: 2018-06-05→ Common Stock (1,493 underlying)
Award
Stock Option (right to buy)
2013-12-23+5,974→ 5,974 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (5,974 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−358→ 0 total
Exercise: $30.21From: 2004-01-12Exp: 2014-01-12→ Common Stock (358 underlying)
Award
Stock Option (right to buy)
2013-12-23+5,535→ 5,535 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (5,535 underlying)
Award
Stock Option (right to buy)
2013-12-23+1,493→ 1,493 total
Exercise: $5.00From: 2008-06-05Exp: 2023-12-22→ Common Stock (1,493 underlying)
Award
Stock Appreciation Right
2013-12-23+95,997→ 95,997 total
Exercise: $5.00Exp: 2023-12-22→ Common Stock (95,997 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−5,974→ 0 total
Exercise: $15.90Exp: 2020-01-10→ Common Stock (5,974 underlying)
Award
Stock Option (right to buy)
2013-12-23+358→ 358 total
Exercise: $5.00From: 2004-01-12Exp: 2023-12-22→ Common Stock (358 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−6,212→ 0 total
Exercise: $30.21Exp: 2015-01-07→ Common Stock (6,212 underlying)
Disposition to Issuer
Stock Option (right to buy)
2013-12-23−1,257→ 0 total
Exercise: $62.80Exp: 2015-11-18→ Common Stock (1,257 underlying)

Footnotes (9)

[F1]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 12, 2004. The option became exercisable with respect to 25% of the underlying shares on the first anniversary of the vesting commencement date of September 1, 2003 and with respect to the remaining 75% of the underlying shares in equal monthly installments over the next three-year period. The expiration date of the option was extended to December 22, 2023.
[F2]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 12, 2004. The expiration date of the option was extended to December 22, 2023.
[F3]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 7, 2005. The option became exercisable in equal monthly installments over the four-year period, beginning on January 1, 2005. The expiration date of the option was extended to December 22, 2023.
[F4]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 18, 2005. The option became exercisable in equal monthly installments over the four-year period, beginning on November 1, 2005. The expiration date of the option was extended to December 22, 2023.
[F5]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 5, 2008. The option became exercisable in equal monthly installments over the three-year period, beginning on June 5, 2008. The expiration date of the option was extended to December 22, 2023.
[F6]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 5, 2008. The expiration date of the option was extended to December 22, 2023.
[F7]The two reported transactions involved an amendment of an outstanding option, resulting in the deemed cancellation of the "old" option and the grant of a replacement option. The option was originally granted on January 10, 2010. The option vests in equal monthly installments over the four-year period, beginning on October 15, 2009. The expiration date of the option was extended to December 22, 2023.
[F8]The reporting person agreed to cancellation of an "old" option, in exchange for a new option having a lower exercise price.
[F9]This award was granted under the Issuer's 2013 Equity Incentive Plan and can be settled in cash or shares of the Issuer's common stock, at the sole discretion of the Issuer. The award vests in full on the two-year anniversary of the grant date.

Documents

1 file

4
edgar.xmlPrimary
FORM 4 -

Issuer

CymaBay Therapeutics, Inc.

CIK 0001042074

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001042074

Filing Metadata

Form type: 4
Filed: Dec 26, 7:00 PM ET
Accepted: Dec 27, 6:43 PM ET
Size: 37.8 KB

View on SEC.gov